CompletedNot Applicable

Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer

France35 participantsStarted 2018-02-26

Plain-language summary

Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are few biomarkers in circulating blood as prognostic or diagnostic markers in pancreatic cancer. The purpose of this study is to determine if the pancreatic tumor mobilization during its resection impacts the quantity of circulating tumor DNA in peripheral and portal blood.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Every patient taken care by Toulouse University Hospital for the resection of a non-metastatic pancreatic adenocarcinoma by whipple resection. * Patient aged over 18 years old * Patient having given his written consent * Patient with social insurance coverage Exclusion Criteria: * Patients who had surgery, but their pathological examination of the resected specimen does not contain adenocarcinoma. * Patient for whom the surgery was not realized (exploratory laparotomy)

What they're measuring

Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.

Timeframe: Kinetic up to one year

Trial details

NCT IDNCT03435536

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-06-20

View on ClinicalTrials.gov More Resectable Pancreatic Cancer trials